Table 1.
Characteristics of the study population
| Characteristics | Control (n = 45) |
AIS (n = 45) |
|---|---|---|
| Age (years) | 58.46 ± 10.4 | 57.48 ± 11.4 |
| Male (n, %) | (75%) | (75%) |
| WBC (×109) | 6.87 ± 1.32 | 10.05 ± 3.38* |
| Neutrophils (%) | 59.90 ± 6.57 | 75.2 ± 10.67* |
| Monocytes (%) | 3.42 ± 0.55 | 2.83 ± 0.92* |
| Lymphocytes (%) | 21.04 ± 7.25 | 20.8 ± 9.63* |
| Eosinophils (%) | 1.19 ± 0.67 | 1.2 ± 1.19 |
| Basophils (%) | 0 | 0 |
| Total cholesterol (mmol/l) | 3.16 ± 0.52 | 4.37 ± 0.78 |
| Triglycerides (mmol/l) | 1.42 ± 0.41 | 1.52 ± 1.21 |
| LDL (mmol/l) | 1.58 ± 0.36 | 2.88 ± 0.76* |
| HDL (mmol/l) | 0.82 ± 0.20 | 1.16 ± 0.29 |
| NIHSS score | — | 8.69 ± 5.67 |
| Previous AIS or TIA (n) | — | 5 |
| Diabetes (n) | 2 | 6 |
| Hypertension (n) | — | 11 |
| Hypercholesterolemia (n) | 0 | 12 |
| Cigarette smoking (n) | 0 | 14 |
| Erythrocytes(×1012/l) | 4.33 ± 0.35 | 4.74 ± 0.46 |
| PLT (×109) | 259.2 ± 62.29 | 221.52 ± 47.6* |
| PT (s) | 11.24 ± 1.04 | 11.03 ± 0.78 |
| APTT (s) | 35.06 ± 2.70 | 31.99 ± 3.52 |
| D-dimer (mg/l) | 41.8 ± 25.4 | 263.07 ± 208.6* |
| Fibrinogen (mg/l) | 2.46 ± 0.43 | 3.07 ± 0.52* |
| Pharmacological therapy | ||
| Antiplatelet (n) | — | 20 |
| Anticoagulant (n) | — | 5 |
| Fibrinolysis (n) | — | 25 |
| ACE inhibitor or ARB (n) | 6 | 18 |
| Statin (n) | 4 | 22 |
The main clinical and laboratory features of 45 healthy controls and 45 patients diagnosed with stroke. Data are presented as numbers (percentages) or the median ± SD
WBC White blood cells, PLTs Platelets
*P < 0.05 vs. healthy control